The August Wellness Index Report, published by Wellness Eternal, spotlights the discipline that determines whether longevity science reaches real people. Translational longevity—the work of closing the gap between laboratory breakthroughs and patient care—is the focus, and its leading voices will converge at the Translational Longevity Summit in Boston, hosted by Boston BioLife and the Healthspan Action Coalition.
The report identifies three key signals: cell science moving from proof of concept to clinical delivery, evidence emerging as the bridge from research to practice, and clinical strategy and systems proving essential to scaling care. These signals underscore that the future of longevity depends not just on discovery but on effective delivery.
Three experts are featured across these vantage points: Dr. Camillo Ricordi of the University of Miami, Dr. David Barzilai of Harvard Medical School, and Dr. Suzie Robertson of Matrix Biologics. Their work exemplifies the shift from bench to bedside.
The Translational Longevity Summit runs October 7–11 at the Harvard Enterprise Research Campus in Boston, hosted by Joseph Krieger of Boston BioLife and Bernard Siegel of the Healthspan Action Coalition. The summit aims to unite laboratory discovery, clinical practice, and community impact.
The report emphasizes that decades of research in transplantation and cell therapy are moving into broader longevity applications. The emphasis is shifting from proof of concept to real clinical delivery, translating foundational science into treatments that can reverse drivers of disease and aging. As longevity claims multiply, the field rewards those who can separate proven science from promising speculation. Evidence becomes the bridge to practice, guiding clinicians, executives, and policymakers.
Even the best therapy fails if the system cannot deliver it safely and consistently. Clinical strategy, operational rigor, and smarter care models are essential to ensure scientific advances reach patients through safe, compliant, and scalable channels.
Dr. Camillo Ricordi, a professor at the University of Miami, anchors the first signal: translational cell therapy moving from laboratory into clinical reality. Dr. David Barzilai, a Harvard Medical School lecturer and longevity medicine physician, focuses on evidence-based and precision medicine, making complex science accessible. Dr. Suzie Robertson, a clinical pharmacist and healthcare strategist, bridges clinical excellence with innovation to improve patient safety and care delivery.
The summit hosts bring deep expertise. Joseph Krieger, president of Boston BioLife, has spent over 25 years in healthcare and life sciences, building an organization that accelerates the integration of cutting-edge technologies into practice. Bernard Siegel, founder of the Healthspan Action Coalition, has been a patient advocate and helped forge the advocacy movement in stem cell and regenerative medicine.
"The future of longevity is translational," said Lindsay O'Neill-O'Keefe, founder of Wellness Eternal. "The breakthroughs are real, but they only matter when they reach people. Discovery is only half the job. Delivery is the rest."
The Wellness Index Report, published monthly, evaluates providers through expert nomination, patient feedback, clinical review, and ongoing performance tracking. The full August report is available at wellnessindexreport.com.
